Adult acute leukemia. Aggressive treatment improves survival

Eyre, Harmon J.; Ward, John H.; Priebat, Dennis A.

doi:10.1002/1097-0142(19830615)51:12+<2460::aid-cncr2820511314>3.0.co;2-y

Cancer

1983

DOI: 10.1002/1097-0142(19830615)51:12+<2460::aid-cncr2820511314>3.0.co;2-y

|View full text |Cite

Adult acute leukemia. Aggressive treatment improves survival

Harmon J. Eyre¹,

John H. Ward²,

Dennis A. Priebat³

Abstract: Although improvements in the management of adults with acute leukemia have lagged behind those seen in the treatment of children, there are clear reasons for optimism. Combination chemotherapy for acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) in adults results in complete remissions in 50–85% of patients. An increasing number of these patients remain in continuous remission for over two years with a significant proportion (15–25%) disease‐free after five years. Those who remain in re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1985

1997

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of children with acute lymphoblastic leukaemia (ALL) who survive free of disease has increased substantially over the last 30 years. By 1984 there was evidence to suggest that this might be due, in part, to the application of more intensive early treatment (Hoelzer et al, 1984;Eyre et al, 1983;Jacobs & Gale, 1984;Kirshner & Preisler, 1984), but there was no information available from large randomized trials. The U.K. Medical Research Council's (MRC) trial for children, UKALL X, was designed to examine the benefit of additional blocks of ' AML-style' intensive treatment, and the MRC Working Party on Leukaemia in Adults decided to use, with minor modifications, the UKALL X design for the next trial for adults: i.e.…”

mentioning

confidence: 99%

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA

1997

View full text Add to dashboard Cite

Summary. The MRC UKALL XA trial for patients aged 15 years and over with acute lymphoblastic leukaemia was designed to evaluate short blocks of intensive ' AML-style' treatment. Between 1985 and 1992, 618 eligible patients were entered into the trial. 450 patients were randomized to receive early intensification at 5 weeks, late intensification at 20 weeks, both, or neither. Unlike the concurrent children's trial, UKALL X, which was of similar design, UKALL XA does not demonstrate a clear benefit for intensification, although there was a significant reduction in the relapse risk due to the early block. The estimated increase in disease-free survival at 5 years was 2% with 95% confidence interval from 1% reduction to 5% increase. There may be a real difference between the effect of these treatments in adults and in children, but this result may be somewhat weakened by poorer compliance, with a greater proportion of adults not receiving the treatment arm to which they were randomized.

show abstract

mentioning

confidence: 99%

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA

1997

View full text Add to dashboard Cite

show abstract

Therapy for acute myeloid leukemia in 119 adults: A comparison of two treatment protocols

Link

Frauer

Ostendorf

et al. 1985

Blut

View full text Add to dashboard Cite

Of 119 patients with acute myeloid leukemia, 69 were treated with Adriamycin, Vincristine and Cytosine Arabinoside (Therapy 1) and 50 with Daunorubicin, Cytosine Arabinoside and 6-Thioguanine (Therapy 2) as well as a consolidation therapy. The maintenance therapy with Cytosine Arabinoside and 6-Thioguanine was the same for both groups. The complete remission rate was 44% for Therapy 1 and 68% for Therapy 2 (p less than 0.05). - The median values for remission duration were 7 and 13 months respectively (p = 0.10); for survival time the median values were 18 and 19 months. These figures show in retrospect that high remission rates can be attained through intensive induction therapy and that longer remission duration is correlated with more aggressive induction therapy. A mild form of maintenance therapy seems to have little effect on the duration of complete remission.

show abstract

Intensive short-term chemotherapy in patients with advanced breast cancer

et al. 1987

View full text Add to dashboard Cite

Aiming at a high complete remission rate with an intensive induction regimen, 27 patients with advanced breast cancer were given three cycles of VAC chemotherapy consisting of vindesine 3 mg/m2 i.v. on days 1 and 12, adriamycin 40 mg/m2 i.v. on days 1 and 12, and cyclophosphamide 200 mg/m2 p.o. on days 3-6 and 14-17 together with medroxyprogesterone acetate (MPA) 1,500 mg p.o. daily during the induction phase and 1,000 mg p.o. thereafter until relapse. These VAC double cycles were repeated twice with 3-weekly intervals for a total induction period of 15 weeks. In responders, including no change, the chemotherapy was discontinued thereafter, and the patients were observed until relapse with a maintenance therapy of MPA 1,000 mg p.o. daily. A complete remission (CR) was achieved in 8 (29.6%) and a partial remission (PR) in 13 (48.2%) of the 27 patients (CR + PR 77.8%). A no change (NC) status was found in 6 patients (22.2%). There were no nonresponders. The median duration of the CR was 20 (5-42) months with two patients still in CR at 33 and 36 months, of the PR 8.3 (4-13.5) months, and of the NC 6.7 (2-13) months. The treatment was tolerated without life-threatening toxicity or interval prolongation by all patients. No dose-limiting cardiac toxicity was observed in these patients regularly controlled by left ventricular ejection fraction (LVEF). The high response rate of this intensive induction regimen warrants further investigation. Complete remission was achieved only in patients without previous chemotherapy, with marked tumor regression after the first chemotherapy cycle and when there was no extensive bone involvement.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adult acute leukemia. Aggressive treatment improves survival

Cited by 7 publications

References 54 publications

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA

Therapy for acute myeloid leukemia in 119 adults: A comparison of two treatment protocols

Intensive short-term chemotherapy in patients with advanced breast cancer

Contact Info

Product

Resources

About